Arpida shares soar on late-stage superbug data

Shares of Switzerland's Arpida soared more than 25 percent this morning after the company announced that its superbug drug iclaprim performed as well as a competing drug from Pfizer in a late-stage trial. Arpida says that a regulatory filing for the therapy--designed to fight MRSA and other tough infections--is on track for later this year.

"We look to discuss the data with the regulatory authorities to define the path forward for the filing of a New Drug Application which we expect to take place in the course of this year," said Arpida CEO Khalid Islam.

- for more on the data, see this release
- here's the Dow Jones report on the study

Related Articles:
Study finds alarming spread of MRSA. Report
MRSA-CA danger to healthcare workers. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.